Head and neck cancer corresponds to tumors located in the upper aerodigestive tract, such as the oral cavity, pharynx and larynx. The most effective treatment consists of high doses of cisplatin chemotherapy and radiotherapy, however, their use is limited due to toxicities caused mainly by oxidative stress. The objective of this study will be evaluate the toxicities caused by cellular oxidative stress in head and neck cancer patients treated with cisplatin. This is an observational prospective quantitative clinical trial with consecutive sampling that will be conducted at Oncology Department of Clinic Hospital / UNICAMP. Head and neck cancer patients who will begin cisplatin antineoplastic treatment (80-100mg/m2 on days 1, 22 and 43) and concurrent radiotherapy will be included in this research. It will be evaluated cisplatin induced hematologic and gastrointestinal disorders, nephrotoxicity, ototoxicity, and hepatotoxicity; cellular oxidative stress will be measured by Amplex Red, MitoSOX Red and Oxidized/Reduced Glutathione tests. Results will be statistically analyzed using Chi-square, Fisher's exact, Mann-Whitney, and ANOVA for repeated measures tests, considering p<0.05.
News published in Agência FAPESP Newsletter about the scholarship: